SCHEMBL10074401

SCHEMBL10074401

COC(=O)c1ccc(O)c2nc3cc(O)c(-c4c(O)cc5nc6c(O)ccc(C(=O)OC)c6nc5c4O)c(O)c3nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA7 P43166 3/20 0.42
CA9 Q16790 3/20 0.42
CA14 Q9ULX7 3/20 0.42
PDK2 Q15119 1/20 0.42
PDK4 Q16654 1/20 0.42
KMT2A Q03164 4/20 0.40
MAPT P10636 4/20 0.40
MEN1 O00255 3/20 0.40
GAA P10253 3/20 0.40
LCK P06239 2/20 0.40
ATM Q13315 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 3/20 0.37
THRB P10828 2/20 0.37
APEX1 P27695 2/20 0.37
RECQL P46063 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10075146 0.85 ESR1 (0.34) KDM4ECA9KMT2AMAPTMEN1
SCHEMBL3724952 0.84 KDM4E (0.57) KDM4ECA12CA1CA2CA7
SCHEMBL3722173 0.79 KDM4E (0.60) KDM4ECA12CA1CA2CA7
SCHEMBL3724957 0.78 KDM4E (0.51) KDM4ECA12CA1CA2CA7
SCHEMBL10075151 0.76 KDM4E (0.42) KDM4ECA12CA1CA2CA7
SCHEMBL10074399 0.76 KDM4E (0.42) KDM4ECA12CA1CA2CA7
SCHEMBL10075134 0.75 KDM4E (0.41) KDM4ECA12CA1CA2CA7
SCHEMBL16968746 0.75 KMT2A (0.34) KMT2AMAPTMEN1TDP1MCL1
SCHEMBL3722178 0.75 KDM4E (0.55) KDM4ECA12CA1CA2CA7
SCHEMBL10074409 0.74 KDM4E (0.40) KDM4ECA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US claimed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US claimed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
WO-2012088438-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL9 KDM4E 1427/4885CA12 2742/4885CA1 1612/4885
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL2L1 KDM4E 709/4885CA12 1916/4885CA1 1382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.